Amrutanjan Health Care Ltd
Amrutanjan Health Care Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Amrutanjan Health Care Ltd's Q2 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q2 FY26 Revenue from Operations: Rs. Q2 FY26 EBITDA: Rs.
From Amrutanjan Health Care Ltd's Q2 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY26 Revenue from Operations: Rs. 117.70 Cr, up 7.08% YoY (Page 22)
- Q2 FY26 Gross Sales: Rs. 132.49 Cr, up 9.76% YoY (Page 22)
- Q2 FY26 Net Sales - OTC: Rs. 112.80 Cr, up 6.15% YoY (Page 23)
- Q2 FY26 Net Sales – Comfy: Rs. 32.78 Cr, slight decline vs Rs. 33.00 Cr YoY (Page 23)
- Q2 FY26 Gross Sales - Beverages: Rs. 5.25 Cr, up 33.93% YoY (Page 24)
- H1 FY26 Revenue from Operations: Rs. 211.75 Cr, up 9.35% YoY (Page 25)
- H1 FY26 Gross Sales: Rs. 239.68 Cr, up 11.86% YoY (Page 25)
- H1 FY26 Net Sales - OTC: Rs. 198.38 Cr, up 10.89% YoY (Page 26)
- H1 FY26 Net Sales – Comfy: Rs. 61.39 Cr, up 3.04% YoY (Page 26)
- Management commentary notes softer Q2 topline due to new GST law effective late September (Page 30)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Sanitary napkin plant:
- Will be commissioned by late Q4 FY26
- Expected to be a strong enabler of Comfy brand profitability and strategic supply
- SAP Implementation for Comfy Plant:
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹150 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Health Care Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key concall takeaways from Morepen Laboratories Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q2 FY26)
Q2’FY26 revenue grew by 12% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Anuh Pharma Ltd (Q2 FY26)
185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key concall takeaways from Anuh Pharma Ltd's Q2 FY26 earnings call — and how it…
- Themis Medicare Ltd (Q2 FY26)
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key concall takeaways from Themis Medicare Ltd's Q2 FY26 earnings call…
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q2 FY26 results?
Q2 FY26 Revenue from Operations: Rs. Q2 FY26 EBITDA: Rs.
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Is Amrutanjan Health Care Ltd planning capital expenditure?
Sanitary napkin plant: - Will be commissioned by late Q4 FY26 - Expected to be a strong enabler of Comfy brand profitability and strategic supply - SAP Implementation for Comfy Plant: - In progr
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.